[when the Congress is in progress] road show of American Cancer Medicine Project

Source: China Association for the promotion of pharmaceutical innovation 2017-11-01 On the morning of October 30, one of the sub sessions of the second China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as "the conference"), the high-profile US cancer drug project roadshow, officially opened Nine innovative companies focusing on cancer drugs from the United States competed to appear, attracting many people from the pharmaceutical and investment circles The roadshow of American cancer drug project is organized by China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") and American Cancer Research Foundation (full name in English: National Foundation for cancer) Research, NFCR, hereinafter referred to as the "foundation") is jointly sponsored by the United States In order to participate in this conference, the representatives of the United States come from major cities in the United States all the way They hope that with the help of the platform of the conference, they can carry out in-depth cooperation with Chinese pharmaceutical investors and jointly promote the development of global pharmaceutical innovation At the beginning of the meeting, Joseph franlin, chairman of the board of directors of the foundation, delivered an opening speech Mr franlin first of all gave high praise and sincere thanks to the organizers of the conference, and believed that with the help of the platform of the conference, the American representatives participating in the conference could find Chinese partners and investment Mr franlin briefly introduced the foundation, which is the largest and most famous cancer research public welfare organization in the United States It has always been committed to funding basic and clinical research and international cooperation in cancer prevention measures, early diagnosis, new therapy and new drug research and development worldwide Since its establishment in 1973, many achievements have been made in the field of tumor research At the same time, Mr franlin introduced that at the opening ceremony of the conference on October 29, the foundation had signed a memorandum of cooperation with the China Council for the promotion of drugs, and the two sides would work together to build a "Sino-U.S platform for innovation and cooperation in cancer medicine" to carry out exchanges and cooperation in scientific research, clinical, industrial and policy fields, so as to enable innovative tumor drugs to serve the clinic as soon as possible and enhance the accessibility of innovative drugs To the benefit of all mankind Following the opening speech by Joseph franlin, chairman of the board of directors, Dr Ba Sujuan, President and chief operating officer of the first stage host foundation, briefly introduced nine innovative companies in the United States, some of which have already joined the National Institutes of health, NIH) has cooperated and started the first phase of clinical practice For some tumor drugs, there will be new research and discovery in the future Dr Ba Sujuan presided over the opening report of Philip Ross, managing director of JPMorgan medical health investment banking department in the first stage on "biomedical market trends and related observations" He briefly introduced the overview of biomedical market, and briefly analyzed several investment cases of JPMorgan William werkmeister, the founding partner of the international cancer Impact Fund (ICIF), took the lead on the stage He introduced that ICIF's investment scale is US $350 million, mainly supporting basic prospective research in the field of cancer The achievements of 60 scientists who have ever supported have produced 57 scientific inventions and incubated 16 companies The second stage of the meeting was presided over by Dr Yang Dajun, chairman and CEO of AXA pharmaceutical Paul Fisher, Ryan Witt, cohava Gelber, Michael Cardone, William Doyle and Kenneth Sorensen respectively introduced the different therapies, research teams and research results at this stage that each company focused on Dr Yang Dajun presided over the second stage of the U.S representative roadshow the U.S cancer drug program is the first cooperation between China pharmaceutical promotion association and the foundation, which is unprecedented in scale and fruitful It is understood that up to the time of publication, three American innovation companies have found interested partners through the platform of the conference, and are in-depth contact at present In the future, the two sides will also conduct in-depth cooperation to jointly promote the research and development of tumor drugs, and build a platform for communication between tumor research and development, clinical community and investment community The cooperation between the two conferences is of great significance to deepen mutual understanding and cooperation between the pharmaceutical research and development circles of the two countries We are convinced that the cooperation between the two sides will not only benefit the common people and cancer patients in their respective countries, but also benefit the global patients, which is of great significance Appendix: brief introduction of the American Cancer Research Foundation (NFCR), founded by Dr Albert St Jerzy, Nobel Prize winner, and Mr Franklin Shaw, lawyer and entrepreneur, is the largest and most famous cancer research public welfare institution in the United States The foundation has been committed to funding basic and clinical research and international cooperation in cancer prevention, early diagnosis, new therapies and new drug development worldwide Since its establishment in 1973, the foundation has provided at least $350 million for innovative scientific research aimed at revealing the mechanism of cancer transformation and public education related to cancer prevention, detection and treatment.